Evidence map›Paper›PMID 39263699›Full record

ArticleBioanalysis2024

Highlights of the 15th Japan Bioanalysis Forum Symposium.

Makoto Niwa, Tomoko Arakawa, Koji Arai, Noriyuki Koyama, Hisanori Hara, Katsutomo Hata, Masayo Hashimoto, Eiichi Shimada, Hiroyuki Shimizu, Yuki Takamatsu and 12 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioanalysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Makoto NiwaDiscovery Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, Kyoto, Japan.ORCID 0000-0002-2355-1222
Tomoko ArakawaClinical Pharmacology and Bioanalytics, Pfizer R&D Japan G.K., Shibuya-ku, Tokyo, Japan.
Koji AraiBioanalysis Department, Mediford Corporation, Itabashi-ku, Tokyo, Japan.
Noriyuki KoyamaTokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, Tokushima, Japan.
Hisanori HaraRW Bioanalysis Consulting, Bottmingen, Switzerland.
Katsutomo HataLaboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Osaka, Japan.
Masayo HashimotoDepartment of Biometrics, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Osaka, Japan.ORCID 0000-0001-6378-5800
Eiichi ShimadaPharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd., Mishima, Osaka, Japan.
Hiroyuki ShimizuDMPK Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan.
Yuki TakamatsuCenter of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Co., Ltd., Fujisawa, Kanagawa, Japan.ORCID 0009-0005-9552-1988
Hitoshi UchiyamaR&D Division, Towa Pharmaceutical Co., Ltd., Settsu, Osaka, Japan.ORCID 0000-0001-9505-1182
Takeru YamaguchiOsaka Laboratory, Sumika Chemical Analysis Service, Ltd., Osaka, Osaka, Japan.
Kenichi YamamotoPharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Wakayama, Japan.
Masaaki KakehiCenter of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Co., Ltd., Fujisawa, Kanagawa, Japan.
Yuu MoriyaCenter of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Co., Ltd., Fujisawa, Kanagawa, Japan.
Hironosuke KurisuClinical Pharmacology and Bioanalytics, Pfizer R&D Japan G.K., Shibuya-ku, Tokyo, Japan.
Hisao NagayaSynplogen Co., Ltd., Kobe, Hyogo, Japan.
Tsunenori NakazawaR&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Shohei NoguchiDrug Safety Research Laboratories, Shin Nippon Biomedical Laboratories, Ltd., Kagoshima, Kagoshima, Japan.
Yuki OdaPharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Hiromi OkamotoR&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Shinsuke UchihashiDrug Development Research Laboratories, Maruho Co., Ltd., Osaka, Osaka, Japan.

Funding

Kyoto Convention & Visitors Bureau Subsidy for convening sustainable meetings & event
6 · The paper itself

Abstract

The 15th Japan Bioanalysis Forum (JBF) Symposium was held in Kyoto, Japan, between 5 and 7 February 2024. The conference theme, 'Toward the new world - Science as a universal endeavor' indicated that universal discussion based on science is making a basis of regulatory and analytical sciences, now internationally harmonized. The symposium discussed a wide range of topics, including ICH M10, quantitative PCR, immunogenicity, peptide LC-MS, e-notebooks, artificial intelligence, reliability standards, carrier development, inviting domestic and overseas experts. Approximately 360 attendees from various fields, including pharmaceutical companies, contract research organizations, academia and regulators, gathered in person or online.

Indexed as

Mass SpectrometryArtificial IntelligenceChromatography, LiquidHumansJapanPeptidesPeptides

Identifiers

PMID39263699
PMCPMC11581173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.